Search Results

You are looking at 81 - 90 of 503 items for :

  • "Adjuvant therapy" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Predictors and Temporal Trends of Adjuvant Aromatase Inhibitor Use in Breast Cancer

Tiffany H. Svahn, Joyce C. Niland, Robert W. Carlson, Melissa E. Hughes, Rebecca A. Ottesen, Richard L. Theriault, Stephen B. Edge, Anne F. Schott, Michael A. Bookman, and Jane C. Weeks

. 5 Coates AS Keshaviah A Thurlimann B . Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 . J Clin Oncol 2007 ; 25 : 486

Full access

Quality Improvement Project: Opportunities for Improvement

Nora M. Hansen, Sally Anne Scherer, and Seema Khan

of 60 cases, care was nonconcordant in 8. Among those cases, 1 patient was advised to have chemotherapy but refused; another patient’s record did not document a recommendation for adjuvant therapy; and 5 patients received treatment but not within the

Full access

Active Systemic Treatment of Pancreatic Cancer

Margaret Tempero

margin,” she said. Dr. Tempero briefly reviewed some of the representative adjuvant therapy clinical trials conducted in pancreatic cancer, focusing primarily on the relatively recent phase III ESPAC-4 trial of gemcitabine/capecitabine 1 and the

Full access

Genomic Medicine Takes the Stage, Again!

Margaret Tempero

reason that in the adjuvant setting, we could probably identify diagnostic tools to predict outcome, and thus need for adjuvant treatment, across all disease sites. Actually, folks are working on that with a fair bit of success. But adjuvant therapy is

Full access

CLO23-040: Electrocardiographic Findings in Cancer Patients Receiving Chemotherapy From the Colombian Coffee Triangle Region

Andres Garcia, David Medina, Alejandra Palacio, Andrés Vallejo, Luz Adriana Díaz, Juan Darío Franco, Tatiana Taborda, and María José Rojas

-IV). In chemotherapy indications, 31.3% were prescribed for palliative care, with the same percentage for adjuvant therapy and 18% for neoadjuvant and hormonal treatment, respectively. The most frequently prescribed antineoplastic agents were taxanes

Full access

Pharmacogenetics of Tamoxifen: Who Should Undergo CYP2D6 Genetic Testing?

Michaela J. Higgins, James M. Rae, David A. Flockhart, Daniel F. Hayes, and Vered Stearns

adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial . Lancet Oncol 2008 ; 9 : 45 – 53 . 48 Coates AS Keshaviah A Thurlimann B . Five years of letrozole compared with tamoxifen as initial adjuvant therapy for

Full access

Ten Years of Progress in Melanoma

John A. Thompson

-positives. PET/CT may be more useful than conventional CT in the workup of patients who have relatively high pretest probabilities of occult metastatic disease (eg, patients with stage IIIB and IIIC melanoma). Treatment Adjuvant Therapy High

Full access

Clinical Consequences of Altering the Definition of HER2-Positive Breast Cancer to Exclude Group 2, HER2-Negative Disease

Steven Sorscher

HER2 copy number is less than 4 signals/cell is that….” 2 Based on the pre-2018 ASCO/CAP HER2 classification, whether being used as adjuvant therapy or therapy for metastatic HER2-positive disease, the FDA-approved anti-HER2 therapies offer truly

Full access

Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer

Nickolas Stabellini, Lifen Cao, Christopher W. Towe, Megan E. Miller, Artur H. Sousa-Santos, Amanda L. Amin, and Alberto J. Montero

,700 breast cancer–related deaths are expected. 2 Due to steady progress in early breast cancer diagnosis and treatment, 5-year overall survival (OS) continues to improve. 3 Accurate estimates of survival and the impact of different adjuvant therapies in

Full access

Systemic Management of Colorectal Cancer

Wells A. Messersmith

treatment with the best chance of success. Adjuvant Therapy Although 11 agents have been approved by the FDA for CRC, only 3 are used in the adjuvant setting (fluorouracil [5-FU], capecitabine, and oxaliplatin) and only 2 (cetuximab and panitumumab